Drug Profile

REGEND 007

Alternative Names: REGEND-007

Latest Information Update: 28 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Preclinical Adult respiratory distress syndrome; Graft-versus-host disease; Pneumonia

22 Jan 2026 Regend Therapeutics plans an early phase I trial for Idiopathic pulmonary fibrosis in China (IV, Infusion) (NCT07359963)
21 Jan 2026 Regend Therapeutics plans phase 0 trial for Chronic obstructive pulmonary disease in China (IV, infusion) in February 2026 (NCT07355868)
20 Dec 2022 Preclinical trials in Adult respiratory distress syndrome in China (Parenteral), prior to December 2022 (Regend Therapeutics pipeline, December 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com